
April 26, 2012
miRagen Publishes Compelling Data Suggesting MIRG-9103 Program May Have Therapeutic Benefits in Metabolic Disorders
April 24, 2012
miRagen Therapeutics Secures $20 Million Series B Financing
April 24, 2012
miRagen Expands Executive Team Adding Drug Development Veteran

|
quick links
|